Monte Rosa Therapeutics, Inc. (GLUE)
GLUE moved a median of +0.12% 30 minutes after news, and -0.71% by the close. How GLUE actually reacts to news — the realized, point-in-time move the market made, measured across 293 labeled events over the last three years with zero look-ahead.
GLUE’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.04% | 44% | 292 |
| 30-min | +0.12% | 52% | 292 |
| 60-min | +0.03% | 50% | 292 |
| to close | -0.71% | 46% | 292 |
| Middle 50% of GLUE reactions | -1.08% to +1.97% |
|---|---|
| Median reaction (30-min) | +0.12% |
| Measured reactions | 293 |
Half of all Monte Rosa Therapeutics, Inc. news events land between -1.08% and +1.97% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when GLUE moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to GLUE's baseline. Nothing else.
Recent GLUE events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.51% | -2.75% | |
| Form 8-K Monte Rosa Therapeutics, For: Oct 01 | SEC filing · Form 8-K | SEC EDGAR | -3.88% | -6.71% | |
| Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk | Press release | GlobeNewswire | -3.88% | -6.71% | |
| Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk | Press release | GlobeNewswire | -3.88% | -6.71% | |
| Form 8-K Monte Rosa Therapeutics, For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | +0.22% | +5.31% | |
| Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391) | Press release | GlobeNewswire | +0.22% | +5.31% | |
| Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.08% | +0.35% | |
| Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.14% | +3.62% | |
| Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer | Press release | GlobeNewswire | -1.88% | -1.82% | |
| Form 10-Q Monte Rosa Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.02% | +0.58% | |
| Form 8-K Monte Rosa Therapeutics, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +1.02% | +0.58% | |
| Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates | Press release | GlobeNewswire | +1.02% | +0.58% | |
| Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.04% | -3.08% | |
| Form 8-K Monte Rosa Therapeutics, For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +2.18% | +5.96% | |
| Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.23% | -1.57% | |
| Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +2.23% | +4.02% | |
| Form 10-Q Monte Rosa Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.15% | -2.17% | |
| Form 8-K Monte Rosa Therapeutics, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -0.15% | -2.17% | |
| Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates | Press release | GlobeNewswire | -0.15% | -2.17% | |
| Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.26% | +5.05% | |
| Form ARS Monte Rosa Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.96% | +1.92% | |
| Form DEF 14A Monte Rosa Therapeutics, For: Apr 29 | SEC filing · Form DEF | SEC EDGAR | +0.96% | +1.92% | |
| Form DEFA14A Monte Rosa Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.96% | +1.92% | |
| Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors | Press release | GlobeNewswire | +0.20% | +0.15% | |
| Form S-8 Monte Rosa Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +0.06% | -0.06% | |
| Form 10-K Monte Rosa Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.92% | -0.68% | |
| Form 8-K Monte Rosa Therapeutics, For: Mar 17 | SEC filing · Form 8-K | SEC EDGAR | +1.92% | -0.68% | |
| Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Press release | GlobeNewswire | +1.92% | -0.68% | |
| Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer | Press release | GlobeNewswire | +0.15% | -1.15% | |
| Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU) | Press release | GlobeNewswire | +0.50% | -3.47% | |
| Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +4.06% | +1.61% | |
| Form S-3ASR Monte Rosa Therapeutics, | SEC filing · Form S-3ASR | SEC EDGAR | +0.08% | -1.33% | |
| Form 8-K Monte Rosa Therapeutics, For: Feb 09 | SEC filing · Form 8-K | SEC EDGAR | -0.74% | -3.71% | |
| Form 8-K Monte Rosa Therapeutics, For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | +1.31% | -1.41% | |
| Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering | Press release | GlobeNewswire | -0.97% | -3.42% | |
| Form 8-K Monte Rosa Therapeutics, For: Jan 07 | SEC filing · Form 8-K | SEC EDGAR | +6.52% | +6.06% | |
| Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects | Press release | GlobeNewswire | +6.52% | +6.06% | |
| Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | -1.07% | +8.39% | |
| Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results | Press release | GlobeNewswire | +6.52% | +6.06% | |
| Form 8-K Monte Rosa Therapeutics, For: Dec 16 | SEC filing · Form 8-K | SEC EDGAR | +6.55% | +5.78% | |
| Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations | Press release | GlobeNewswire | +6.55% | +5.78% | |
| Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results | Press release | GlobeNewswire | +6.55% | +5.78% | |
| Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases | Press release | GlobeNewswire | +0.04% | +12.30% | |
| Form 10-Q Monte Rosa Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.04% | +4.92% | |
| Form 8-K Monte Rosa Therapeutics, For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -0.04% | +4.92% | |
| Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates | Press release | GlobeNewswire | -0.04% | +4.92% | |
| Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.71% | -5.26% | |
| Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases | Press release | GlobeNewswire | +0.58% | +7.12% | |
| Form 8-K Monte Rosa Therapeutics, For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | -3.27% | -3.08% | |
| Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases | Press release | GlobeNewswire | -3.27% | -3.08% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the GLUE section they belong to.
Where else GLUE is measured.
GLUE earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Monte Rosa Therapeutics, Inc.'s median reaction calculated?
Every labeled GLUE news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 293 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of GLUE's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does GLUE's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.